| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
|
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
| US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(2 years ago) | |
|
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(1 year, 9 months ago) | |
| US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(1 year, 6 months from now) | |
|
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(2 years from now) | |
Zetia is owned by Organon.
Zetia contains Ezetimibe.
Zetia has a total of 10 drug patents out of which 8 drug patents have expired.
Expired drug patents of Zetia are:
- US5846966
- US5846966*PED
- USRE37721*PED
- USRE42461*PED
- US7030106
- US7030106*PED
- USRE37721
- USRE42461
Zetia was authorised for market use on 25 October, 2002.
Zetia is available in tablet;oral dosage forms.
Zetia can be used as reduction of elevated plasma sterol and/or stanol levels in a mammal, to reduce plasma cholesterol levels in a mammal, to reduce plasma cholesterol levels by admin ezetimibe in combo with cholesterol biosynthesis inhib selected from group consisting of hmg coa reductase inhibitors incl simvastatin.
The generics of Zetia are possible to be released after 30 April, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: To reduce plasma cholesterol levels by admin ezetimibe in combo with cholesterol biosynthesis inhib selected from group consisting of hmg coa reductase inhibitors incl simvastatin; Reduction of elevat...
Dosage: TABLET;ORAL
ZETIA family patents
